From what we can see, insiders were net buyers in TScan Therapeutics, Inc.'s (NASDAQ:TCRX ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While ...

Amgen and TScan Therapeutics have announced a multi-year collaboration aimed at identifying new targets for Crohn’s disease. The partnership will utilise TScan’s target discovery platform, TargetScan, ...

WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement ...

Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no ...

Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to ...

WALTHAM, Mass.--(BUSINESS WIRE)--TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patient’s own T cells to recognize ...

Amgen Inc AMGN and TScan Therapeutics Inc TCRX announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in ...

BOSTON--(BUSINESS WIRE)--TScan Therapeutics, dedicated to unleashing the power of the immune system through life-changing T cell therapies, today announced its Series B financing, with over $48 ...

Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy ...

Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study of TSC-101 this month Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., today, June 22, at 8:30 ...